CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
CSL 和 Arcturus Therapeutics 宣布 Nature Communications 已发布关键数据，证明了 COVID-19 疫苗的功效和耐受性
- Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan.
- These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.
- 数据是在日本批准世界上第一款成人自扩增（sa-mRNA）COVID-19 疫苗之后发布的。
- 这些结果补充了最近公布的 ARCT-154 数据，这些数据表明，与传统 mRNA COVID-19 疫苗增强剂相比，免疫原性优于 Omicron BA 4/5，以及后续数据，与传统 COVID-19 mRNA 疫苗增强剂相比，免疫持续时间更长。
KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ -- Global biotechnology leader CSL ((ASX:CSL, OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
宾夕法尼亚州普鲁士国王和圣地亚哥，2024年5月20日 /PRNewswire/ — 全球生物技术领导者CSL（澳大利亚证券交易所股票代码：CSL，场外交易代码：CSLLY）和Arcturus Therapeutics（纳斯达克股票代码：ARCT）今天宣布 自然通讯 已经公布了一项评估ARCT、154、一种新型自扩增（sa-mRNA）COVID-19 疫苗和世界上第一个获批的sa-mRNA COVID-19 疫苗的安全性、免疫原性和有效性的1/2/3a/3b期综合研究的结果。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。